

Frequently Asked Questions

What is the CCRM International Regenerative Medicine SuperPitch VII?

The SuperPitch Program is an initiative of the Centre for Commercialisation of Regenerative Medicine (CCRM) Australia, which has been adopted by all the hubs and is now a global event. The SuperPitch is designed to identify and provide support for the development and translation of high-quality projects from proof-of-concept through to clinical trials. The projects will contribute to new regenerative medicine approaches for improving global health. They will also generate commercial returns, helping create the high-paying jobs of the future and drive economic growth where the hubs are based.

What is CCRM?

CCRM supports the commercialization of regenerative medicine-based technologies, and cell and gene therapies, with strategic funding, dedicated infrastructure and specialized business and scientific expertise.

CCRM was established in Canada in 2011 . By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services through its CDMO subsidiary, [OmniaBio Inc.](#), and scaling emerging companies by catalyzing investment, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.

CCRM Australia is the Australian Hub of CCRM and was incorporated in 2022. Established as a not-for-profit with an international focus, CCRM Australia's mission is to address bottlenecks in the translation and commercialization of regenerative medicine discoveries in Australia, many of which have the potential to cure some of the most devastating and costly diseases in the world today.

CCRM Nordic is based in Sweden and was incorporated in 2023. Much like the other CCRM hubs, CCRM Nordic aims to support academic, small, and large industrial ATMP developers to translate research and early-stage clinical programs into treatments for patients.

Offerings and Focus

Does the SuperPitch have a specific disease or therapeutic focus?

The SuperPitch will accept any applications with a regenerative medicine focus related to any disease area. Applications with an emphasis on disease areas that are serious and have a high unmet need will be prioritized along with projects that have strong commercial potential.

What type of projects are funded?

The SuperPitch identifies projects requiring support to progress novel academic and biotechnology approaches from proof-of-concept through to the clinical trials stage. There must be a clear value proposition for the proposed product, and differentiating features from currently available solutions.

Projects that involve basic research, as well as pre-clinical and clinical work, will be considered, as will platform technologies.

What definition is used for “regenerative medicine”?

Regenerative medicine includes technologies and therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure.

Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools,

enabling technologies such as vector production, automated analytical assays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic areas.

What projects are out of scope for the SuperPitch?

Projects that do not clearly meet the criteria will not be considered.

How does the SuperPitch panel decide on what projects to fund?

Each of the participating Venture Capital (VC) and fund managers will be deciding what to fund based on their criteria. Important general criteria will include, but are not limited to, factors such as strong patentability, clear market need, proof-of-concept data, and clear competitive advantage.

While projects that have partial funding are viewed favourably, no source of external or matching funding is required for involvement in the SuperPitch.

What is expected of an inventor or lead investigator?

We anticipate the Applicant and their research team is willing to participate in mentorship and engage constructively with the advice and support process provided by the SuperPitch Partners. Inventors are also expected to allow the CCRM hubs to promote them and their organization in posts on social media related to this event.

What are the expectations with respect to experimental data?

Projects will be assessed on a case-by-case basis depending on their technology readiness level. Projects should not be based purely on published, non-validated data.

Will this mechanism be biased toward mass or niche market needs?

The SuperPitch is open to regenerative medicine applications that address any disease state and all therapeutic modalities/market needs. Applications will be assessed based on the strength of the application according to selection criteria.

Eligibility Criteria

Who can apply?

Entities eligible for support from the SuperPitch must be from or affiliated to Australia, Canada or from the Nordic countries and include individuals affiliated with:

- medical research institutes;
- universities;
- corporate Commonwealth entities;
- corporations.

Can a multinational company be a partner of an applicant?

Multinational companies can be partners in an application with an eligible entity. The IP would need to reside with the applicant, which would not be the big pharma partner. However, certain VCs and fund managers may have specific requirements.

Do the projects have to be submitted through an institution or solely through an SME or could it be both?

It can be any of the above.

Expressions of Interest (EOI)

Where do I find the EOI form?

The EOI form can be found at <https://ccrmnordic.se/news/ccrm-international-regenerative-medicine-superpitch-vii>.

Potential applicants are encouraged to discuss their applications with any CCRM hub contact person at any time.

Who will review EOIs?

Eligible EOIs will be reviewed by experts at the CCRM hubs. The EOI will include a half-page summary, which will be shared to gauge the interest of potential VCs and fund managers. The full EOIs may also be provided to potential VCs and fund managers subject to interest.

Can I submit an EOI for a project that I have already submitted as an application to another granting body, such as a government funding source?

Applications will be accepted for the SuperPitch regardless of alternative sources of funding that have been sought or won for that project.

If my application was unsuccessful at this SuperPitch, can I resubmit it to future SuperPitch events?

Yes. Unsuccessful applicants are encouraged to re-apply for future SuperPitch events once any shortcomings identified by the review panels in previous applications are shown to have been adequately addressed.

Applicants also have the opportunity to work with the CCRM hubs to correct any shortcomings.

Which projects are more likely to receive funding?

With a variety of independent investors, it is difficult to anticipate criteria for success. Funders will support projects in which they see the potential for a return on investment, whether that is an early-stage project with a promising concept or a project with more validation and a clear development path. The CCRM hubs will provide non-financial support to all applicants.

The SuperPitch Process

Assistance offered by CCRM hubs

The CCRM hubs will assist shortlisted candidates to improve the overall quality of their final pitch to the investment committee. This may include in the areas of commercialization, market analysis, and supply chain logistics or to address specific comments in the initial review. The CCRM hubs can assist directly or facilitate discussions with our allied partners who are willing to provide advice.

SuperPitch Handbook

Candidates will receive a SuperPitch Handbook in the lead-up to the event.

This Handbook will include bios of all VCs and fund managers in attendance for your pitch. Multiple representatives from each company may attend. Candidates will be informed separately of any last-minute changes to the attendance list.

Funders will also receive handbooks prior to the event, containing the details of each candidate and their project.

The Pitch

Pitches will be conducted over the video conferencing application Teams, with a “waiting room” activated to allow the organizers to control access to the “pitching room”. Candidates are welcome to invite as many people to attend as they wish, but only those on the guest list will be allowed access.

Candidates are advised to enter the waiting room at least five minutes before their pitch is due to commence. They will be granted access to the pitching room when the panel is ready.

A total of 45 minutes is allocated to each candidate, including the presentation and subsequent discussion. Candidates are advised to spend 25-30 minutes presenting their pitch and to allow 15 minutes of discussion afterwards. However, candidates are welcome to spend less time presenting to allow more time for discussion.

After the Pitch

Immediately after the candidate has left the pitching room, panellists will continue to discuss the pitch and agree on points of preliminary feedback. This feedback will be provided to the candidate shortly after the event.

Before the event, candidates will have been asked to provide presentation material/slide decks to CCRM. These materials may be distributed after the pitch to interested VCs and fund managers for review. Funders will also be asked to provide additional feedback and state if they are interested in further discussions with candidates.

Anonymized feedback will be collated and returned to the candidates along with the contact details of interested funders and the offer of an e-introduction if the candidate prefers. Candidates and their potential funders are then expected to continue discussions. If necessary, this can be supported by the relevant CCRM hub.

Funding and IP

Do the funds have to be spent on projects at any of the CCRM hubs?

No. Funding from the SuperPitch Program is not by any means tied to CCRM and can be spent anywhere that meets the needs of the candidate. Note that funders may have their own restrictions. These will be negotiated with successful candidates.

Is there a time period to spend the money?

No time period will be assigned by the SuperPitch. However, funders may have specific time periods in mind. These will be negotiated with successful candidates.

How will IP be protected during the application and funding process?

EOIs are disclosed on a non-confidential basis and should not contain sensitive data or material. Participants will be expected to provide slide decks for distribution to the CCRM hubs on the day of the pitch, at the latest. These will be expected to align with the deck used for the presentation, although some sensitive information may be removed. The decks will be shared with interested funders after the event. Confidentiality Disclosure Agreements may be entered into with applicants whose projects move beyond the EOI stage to allow for a complete review and assessment of your project.

Who owns the IP?

All IP related to the project defined in the EOI and pitch is owned by the applicant, subject to any arrangements it has with third parties. Inventorship will be determined based on standard protocols.

If IP is generated as part of a funded project that is saleable to an overseas interest, would that be permitted?

Yes. This is up to the funders.


Who pays for patent applications?

Patenting/protection of the IP will be the responsibility of the successful applicant.

Will the hubs and/or venture partners require a return on investment?

Initial involvement in the SuperPitch is on a service basis. If a venture partner and applicant enter into a commercial arrangement as the result of a SuperPitch event, then any requirement for return on subsequent investment will be negotiated outside of the SuperPitch mechanism.

How will the project be assessed in the SuperPitch?



Non-funding support

The CCRM hubs are able to provide continued support to all SuperPitch applicants on a fee-for-service basis, regardless of their success at receiving funding. Please discuss with CCRM contact persons for more information.

Connecting with the SuperPitch Team

Further questions can be directed to:

Stephanie Mattsson, Director of Venture Development, CCRM Nordic,
stephanie.mattsson@ccrmnordic.se

Chih Wei Teng, Vice President of Corporate Development, CCRM Australia,
chihwei.teng@ccrmaustralia.com.au

Erik Kragegaard, Senior Associate, CCRM Enterprises Inc.,
erik.kragegaard@ccrm.ca

Check <https://ccrmnordic.se/news/ccrm-international-regenerative-medicine-superpitch-vii> for updates.